Derma Sciences Inc.

Derma Sciences to Present at the Ladenburg Thalmann 2016 Healthcare Conference

Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that Stephen T. Wills, the Company’s Executive Chairman and Interim Principal Executive Officer, will present at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27th at 8:30 a.m. Eastern time. The program includes a formal presentation followed by a “fireside chat.” The conference is being held at the Sofitel New York in New York City.

To listen to the presentation, investors may visit the investor relations section of Derma Sciences’ website at www.dermasciences.com. An archived audio of the presentation will also be available on Derma Sciences’ website for 90 days.

About Derma Sciences, Inc.

Derma Sciences is a tissue regeneration company focused on patent-protected and proprietary advanced wound and burn care treatments. The Company’s lead products include TCC-EZ®, a gold-standard total contact casting system for diabetic foot ulcers, and its MEDIHONEY® product line, the leading brand of honey-based dressings for the management of wounds and burns. It is also engaged in the development and commercialization of novel proprietary regenerative products derived from placental/birth tissues for use in a broad range of clinical applications including the treatment of complex chronic wounds, acute wounds and localized areas of injury or inflammation, in addition to filling soft tissue defects or voids. These products are used in orthopedic, spinal and ocular surgical procedures, among others. The Company also offers a full product line of traditional dressings. For more information, please visit www.dermasciences.com.

EN
21/09/2016

Reports on Derma Sciences Inc.

 PRESS RELEASE

INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Into ...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Derma Sciences, Inc. (NASDAQ:DSCI) stock prior to January 10, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Derma Sciences to Integra LifeSciences Holdings Corporation (NASDAQ: IART). Under the terms of the transaction, Derma Sciences common shareholders will receive $7 per share, while holders of Series A ...

 PRESS RELEASE

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Propo...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Derma Sciences, Inc. (Nasdaq: DSCI) (“Derma Sciences” or the “Company”) relating to the proposed buyout of Derma Sciences by Integra LifeSciences Holdings Corporation. Under the terms of the agreement, Derma Sciences common shareholders will receive $7 per share, while holders of S...

 PRESS RELEASE

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Pr...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Derma Sciences, Inc. (Nasdaq: DSCI) (“Derma Sciences” or the “Company”) relating to the proposed buyout of Derma Sciences by Integra LifeSciences Holdings Corporation. Under the terms of the agreement, Derma Sciences common shareholders will receive $7 per share, while holders of S...

 PRESS RELEASE

INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Into ...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Derma Sciences, Inc. (NASDAQ:DSCI) stock prior to January 10, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Derma Sciences to Integra LifeSciences Holdings Corporation (NASDAQ: IART). Under the terms of the transaction, Derma Sciences common shareholders will receive $7 per share, while holders of Series A ...

 PRESS RELEASE

DERMA SCIENCES, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Bri...

DALLAS--(BUSINESS WIRE)-- Former United States Securities and Exchange Commission attorney Willie Briscoe is investigating potential claims against the Board of Directors of Derma Sciences, Inc. (“Derma”) (NasdaqCM: DSCI) concerning the acquisition by Integra LifeSciences Holdings Corporation. Under the terms of the agreement, Derma’s common shareholders will only receive $7.00 per Derma share owned. This consideration is significantly lower than at least one analyst’s estimated value of $8.50 per share. Holders of Derma’s Series A Co...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch